Google
×
AllImagesShoppingNews Maps Videos Books
Search tools

Lenalidomide Market Size & Share | Trends Report, 2024 – 2032

Global Market Insights Inc.
The lenalidomide market size was valued at USD 18 billion in 2023 and is anticipated to register a CAGR of 5.1% between 2024 and 2032 owing to growing trend...
9 months ago

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

The New England Journal of Medicine
An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of transplantation-eligible patients
11 months ago

Revlimid: Dosage, side effects, uses, and more

MedicalNewsToday
Revlimid (lenalidomide) is a brand-name prescription drug used to treat five types of cancer. It comes as a capsule. Learn about side...
62 months ago

The High Cost of Oral Anticancer Drugs: What Does the Future Hold?

Cancer Network
ONCOLOGY Co-Editor-in-Chief Julie M. Vose, MD, MBA, explores high drug costs and financial toxicity.
27 months ago

Dr. Reddy's Laboratories Announces the Launch of Lenalidomide Capsules in the U.S. With Two of Six Strengths Eligible for First-to-market, 180-day Exclusivity

Business Wire
Dr. Reddy's is eligible for first-to-market, 180 days of generic drug exclusivity for Lenalidomide Capsules in 2.5 mg and 20 mg strengths.
26 months ago

Bristol Myers Squibb's Revlimid finally faces competition in the U.S. with Teva's generic launch

FiercePharma
Sales of Bristol Myers Squibb's Revlimid crescendoed at $12.8 billion in 2021, the final year of exclusivity for the multiple myeloma...
32 months ago

New Generic will Cut into BMS’s Top-Earning Cancer Drug

BioSpace
Bristol Myers Squibb's moneymaker cancer drug Revlimid has finally found a competitor in Israel-based Teva Pharmaceuticals' generic version,...
32 months ago

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

The Lancet
Patients with multiple myeloma treated with lenalidomide maintenance therapy have improved progression-free survival, primarily following...
71 months ago

The Medicine Is a Miracle, but Only if You Can Afford It (Published 2023)

The New York Times
A wave of new treatments have cured devastating diseases. When the costs are too much, even for the insured, patients hunt for other ways to...
21 months ago

Cigna Removes Brands in Favor of Generics for 2023

Managed Healthcare Executive
Cigna and Express Scripts have released their Standard Drug List for 2023, removing or excluding 42 branded therapies mostly in favor generics, and moving 11...
25 months ago